Navigation Links
Initial trials on new ovarian cancer tests exhibit extremely high accuracy
Date:8/11/2010

Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

"Because ovarian cancer is a disease of relatively low prevalence, it's essential that tests for it be extremely accurate. We believe we may have developed such a test," said John McDonald, chief research scientist at the Ovarian Cancer Institute (Atlanta) and professor of biology at Georgia Tech.

The measurement step in the test, developed by the research group of Facundo Fernandez, associate professor in the School of Chemistry and Biochemistry at Tech, uses a single drop of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance. The test looks at the small molecules involved in metabolism that are in the serum, known as metabolites. Machine learning techniques developed by Alex Gray, assistant professor in the College of Computing and the Center for the Study of Systems Biology, were then used to sort the sets of metabolites that were found in cancerous plasma from the ones found in healthy samples. Then, McDonald's lab mapped the results between the metabolites found in both sets of tissue to discover the biological meaning of these metabolic changes.

The assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100 percent accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition it registered neither a single false positive nor a false negative

The group is currently in the midst of conducting the next set of assays, this time with 500 patients.

"The caveat is we don't currently have 500 patients with the same type of ovarian cancer, so we're going to look at other types of ovarian cancer," said Fernandez. "It's possible that there are also signatures for other cancers, not just ovarian, so we're also going to be using the same approach to look at other types of cancers. We'll be working with collaborators in Atlanta and elsewhere."

In addition to having a relatively low prevalence ovarian cancer is also asymptomatic in the early stages. Therefore, if further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.


'/>"/>

Contact: David Terraso
david.terraso@comm.gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert

Related biology news :

1. HSBC Climate Partnership yields initial research findings
2. Nervy research: Researchers take initial look at ion channels in a model system
3. Fish fend off invading germs with an initial response similar to the one found in people
4. Faster, cheaper way to find disease genes in human genome passes initial test
5. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
6. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
7. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
8. Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
9. Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies
10. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
11. Pitt gets $12 million DoD contract for regenerative medicine treatment trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... , March 28, 2017 Biostage, ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, today announced that Jim McGorry, CEO ... and BioEngineering panel at the MassBio 2017 ... 2:30 PM ET in Cambrige, Massachussetts. The 3D ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic ... time. A recent study published in STEM CELLS suggests that human neural stem ... stem cells to produce more neural cells. , Strategies involving transplantation of ...
(Date:3/28/2017)... , ... March 28, 2017 ... ... launch its brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules ... and certified by National Sanitation Foundation (NSF). , As fully integrated weighing ...
(Date:3/28/2017)... ... March 28, 2017 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. ... “As we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease ...
Breaking Biology Technology: